Pipeline

NervGen’s lead therapeutic candidate, NVG-291, is a first-and potentially best-in-class neuroreparative peptide targeting the inhibitory mechanisms associated with chondroitin sulfate proteoglycans (CSPGs). NVG-291 is being evaluated in the Phase 1b/2a CONNECT SCI Study, where NVG-291 demonstrated the ability to increase function, independence, and quality of life in individuals with chronic spinal cord injury up to ten years after injury. NervGen is also evaluating a discovery lead, NVG-300, in preclinical models of neurotraumatic and neurologic conditions with significant unmet medical need.

Note:
– Preclinical development for traumautic brain injury funded and conducted by the U.S. Department of Defense via the Walter Reed Army Institutute of Research (WRAIR).
– Preclinical development for traumatic hearing loss funded and conducted by the U.S. Department of Defense via the 59th Medical Wing.
– Discovery lead, NVG-300, developed and discovered internally.

NervGen Pharma Corp (“NervGen”) (TSXV: NGEN) (NASDAQ: NGEN), is a
clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. NervGen’s lead therapeutic candidate, NVG-291, is a
first- and potentially best-in-class subcutaneously administered candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with
spinal cord injury. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.

Contact

112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4

Phone: (778) 731-1711
Email: [email protected]

Subscribe for Updates